Efficacy and safety of dosimetry-based, personalized 177 Lu-DOTATATE PRRT of neuroendocrine tumours: results of P-PRRT trial (EANM 2026) - Sep 29, 2026 - Abstract #EP-0864; P2 | "Personalized PRRT was feasible, delivering the intended renal absorbed dose allowing to increase activity and tumour dose in most patients. Despite inclusion of a heterogeneous population and patients with baseline renal impairment, survival outcomes were comparable to NETTER-1. Higher administered activity was not associated with increased toxicity, supporting the safety of a personalized approach based on renal dosimetry."
Clinical • Hematological Malignancies • Myelodysplastic Syndrome • Neuroendocrine Tumor • Oncology • Renal Disease • Solid Tumor • SSTR
|
|
S. Kurkowska 1; M. Morin 2, 3; C. Uribe 1; A. Beaulieu 2, 3; F. Arsenault 2, 3; G. April 2, 3; F. Buteau 2, 3; J. M. Beauregard 2, 3
|